Senti Biosciences Holdings, Inc. Common Stock

Day range

$0.17 – $0.19

Open

$0.19

Prev close

$0.19

Volume

8.6M

Market cap

$5.87M

Shares out

31.15M

P/E

—

P/S

107.59

P/B

-1.74

P/FCF

—

ROE

1457.3%

ROA

-149.7%

Debt/Equity

-1.17

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsOct 15, 2026

  At the reconvened Annual Meeting, the Company's stockholders: (i) elected three Class I directors, Timothy Lu, M.D., Ph.D., Edward Mathers, and Frances D. Schulz, to the Company's board of directors... (ii) ratified the appointment of KPMG LLP... (iii) approved... the issuance of more than 19.99%... (iv) approved the Agreement and Plan of Merger... and (v) approved an amendment... to effect a reverse stock split.

• Shareholder meeting noticeOct 13, 2026

  The Meeting will be reconvened on Thursday, October 15, 2026 at 8:00 a.m., Pacific time, virtually via the Internet at www.virtualshareholdermeeting.com/SNTI2026. The record date for the Annual Meeting remains September 23, 2026.

• Director departureSep 24, 2026

  On September 23, 2026, Brenda Cooperstone, Ph.D., notified the Board of Directors (the "Board") of Senti Biosciences Holdings, Inc. (the "Company") of her decision to resign from the Board, effective immediately. Dr. Cooperstone's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

• Debt issuanceSep 4, 2026

  On September 3, 2026, Senti Holdings, Inc. ... completed the previously announce[d] issuance and sale to NSG BioInnovation Fund, L.P. ... of $2.0 million in aggregate principal amount of its Senior Secured Convertible Notes.

• Listing deficiency noticeSep 2, 2026

  “The Company received (1) a written notice ... notifying the Company that, for the last 30 consecutive trading days, the closing bid price ... had closed below the minimum bid price requirement of $1.00 per share ... and (2) a written notice ... notifying the Company that, based on the Company's stockholders' deficit of $3,401,000 as of June 30, 2026, it is no longer in compliance with the minimum stockholders' equity requirement of $2.5 million.”

Days to cover

1.0

Short interest

487.17K

Avg volume

1.93M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight
  positiveGlobeNewswire Inc.· Dec 4, 2025
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amerant Bancorp Inc. - AMTB
  negativeGlobeNewswire Inc.· Jun 2, 2025
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
  negativeGlobeNewswire Inc.· Jun 2, 2025
• Senti Bio to Present at the Citizens JMP Life Sciences Conference
  positiveGlobeNewswire Inc.· Apr 30, 2025
• NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight
  positiveGlobeNewswire Inc.· Feb 28, 2025